Belimumab in Systemic Lupus Erythematosus: From B-Cell Biology to Disease Modification.

In BLISS-76, SRI response rates at week 76 remained numerically higher with belimumab than with placebo but did not reach statistical significance, and differences between the two active doses were generally modest across secondary endpoints [ 75 , 76 , 77 ].

also in 111,027 other papers